TRAVERE THERAPEUTICS, INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+73.4% +$55M
$130M
Cost of Revenue↑+0.0% +$0
$3M
R&D↓-6.8% -$4M
$58M
SG&A↑+46.3% +$32M
$102M
D&A↑+50.0% +$6M
$18M
Operating Income↑+144.4% +$81M
$25M
EBITDA↑+50.0% +$6M
$18M
Interest Expense↓-18.5% -$521K
$2M
Interest Income↓-31.7% -$1M
$3M
Other Income/Expense↓-6.3% -$33K
$487K
Pretax Income↑+146.9% +$81M
$26M
Tax Provision
$921K
Net Income↑+146.9% +$81M
$26M
Operating Margin↑+104.4pts
15.1%
Net Margin↑+102.7pts
15.6%
Effective Tax Rate↓-0.1pts
0.0%
Deferred Tax Liabilities
—
ETR (Continuing Operations)↓-2.0pts
-2.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-3.0pts
-1.4%
ETR Foreign Differential (pp)↓-9.7pts
-11.8%
Operating Lease Cost↑+0.0% +$0
$1M
Revenue YoY Variation↑+7.4pts
73.4%
Income YoY Variation↑+105.0pts
144.4%
Revenue QoQ Variation↓-40.2pts
-21.3%
Income QoQ Variation↑+280.0pts
297.1%